[1] Combs DL, O’Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results[J]. Ann Intern Med, 1990,112(6): 397-406.
[2] Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months[J]. Am Rev Respir Dis, 1991,143(4): 700-706.
[3] Barnett GD, Grzybowski S, Styblo K. The current risk of contracting evolutive tuberculosis, in Saskatchewan, according to the state of previous tuberculin tests and x-ray image[J]. Bull Int Union Tuberc, 1971, 45: 55-79.
[4] Canetti G, Sutherland I,Svandova E. Endogenous reactivation and exogenous reinfection: their relative importance with regard to the development of non-primary tuberculosis[J]. Bull Int Union Tuberc, 1972, 47:116-134.
[5] Kim BJ, Lee SH, Lyu MA, et al. Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, Chae GT, Kim EC, Cha CY, Kook YH. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (rpoB) [J]. J Clin Microbiol, 1999, 37(6): 1714-1720.
[6] Frothingham R, and WA Meeker-O’Connell. Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats[J]. Microbiology, 1998, 144:1189-1196.
[7] Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology[J]. J Clin Microbiol, 1997, 35(4): 907-914.
[8] van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM. Strain Identification of Mycobacterium tuberculosis by DNA Fingerprinting: Recommendations for a Standardized Methodology[J]. J Clin Microbiol, 1993, 31(2): 406-409.
[9] van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, Beyers N, van Helden PD. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment[J]. N Engl J Med, 1999,341(16): 1174-1179.
[10] Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ; Tuberculosis Trials Consortium.Recurrent tuberculosis in the United States and Canada relapse or reinfection?[J]. Am J Respir Crit Care Med, 2004, 170(12): 1360-1366.
[11] Shamputa IC, Van Deun A, Salim MA, Hossain MA, Fissette K, de Rijk P, Rigouts L, Portaels F. Endogenous reactivation and true treatment failure as causes of recurrent tuberculosis in a high incidence setting with a low HIV infection[J]. Trop Med Int Health, 2007,12(6): 700-708.
[12] 沈国妙, 薛桢, 沈鑫, 桂晓红, 王奕峰, 孙斌, 沈梅, 梅建, 高谦.利用结核分枝杆菌基因型分型技术研究外源性再感染在结核病复发中的作用[J].中华结核和呼吸杂志,2006,29(2):79-82.
[13] Sonnenberg P, Murray J, Shearer S, Glynn JR, Kambashi B, Godfrey-Faussett P. Tuberculosis treatment failure and drug resistance-same strain or reinfection?[J]. Trans R Soc Trop Med Hyg, 2000, 94(6): 603-607.
[14] Bandera A, Gori A, Catozzi L, Degli Esposti A, Marchetti G, Molteni C, Ferrario G, Codecasa L, Penati V, Matteelli A, Franzetti F. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis[J]. J Clin Microbiol, 2001, 39(6): 2213-2218.
|